Axsome Therapeutics: A Conditional Buy Built On SG&A Discipline

Impact · against what's priced in

AXSM is viewed as a self-sustaining entity with significant upside potential from Alzheimer's and narcolepsy indications. The investment thesis now shifts from binary clinical risk to operational efficiency and SG&A management.

AXSM+0.50

No priced-in read yet

In context

The transition to a self-sustaining model with three products and a pipeline capable of adding $375M+ in annual revenue provides a strong growth trajectory, provided SG&A costs are disciplined.

Read from the article alone

• biotech
• revenue growth
• pharmaceuticals
• AXSM
• alzheimers
• cns drugs
• narcolepsy
• pipeline
• sg and a

Search tags